Company: CMND
Filing Date: 2025-09-19
Form Type: F-1
Source: 0001213900-25-089545
Chunk: 51

Company: Clearmind Medicine Inc.
Filing Date: 2025-09-19
Form: F-1
Chunk 51
---
 issue. |

| (d) | The undersigned registrant hereby undertakes that: |

| (1) | That for purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4), or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective. |

| (2) | That for the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. |

<div align='center'>II-4

EXHIBIT INDEX</div>

| EXHIBIT 
 NUMBER  |     | EXHIBIT DESCRIPTION                                                                                                                                                                                                                                                                                                                            |
| 3.1     |     | Articles of Association of the Registrant, as currently in effect (incorporated herein by reference to Exhibit 3.1 to the registrant’s registration statement on Form F-1, as amended, filed with the SEC on August 18, 2022 (File No. 333-265900))                                                                                            |
| 5.1*    |     | Opinion of Daniel Bloch,                                                                                                                                                                                                                                                                                                                       
 Canadian counsel to the Registrant, as to the validity of the common shares                                                                                                                                                                                                                                                                    |
| 10.1    |     | Form of Indemnification Agreement (incorporated herein by reference to Exhibit 10.1 to the registrant’s registration statement on Form F-1, as amended, filed with the SEC on September 20, 2022 (File No. 333-265900))                                                                                                                        |
| 10.2    |     | Omnibus Stock Award Plan (included as Exhibit 99.1 to our Registration Statement on Form S-8 as filed with the Securities Exchange Commission on December 9, 2024, and incorporated herein by reference).                                                                                                                                      |
| 10.3    |     | Framework Research and Option Agreement with Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., dated October 1, 2021 (incorporated herein by reference to Exhibit 10.3 to the registrant